Literature DB >> 15086601

Correlation between plasma levels of matrix metalloproteinase (MMP)-9 /MMP-2 ratio and alpha-fetoproteins in chronic hepatitis carrying hepatitis B virus.

Tae-Wook Chung1, Jeong-Ran Kim, Jeong-Il Suh, Young-Choon Lee, Young-Chae Chang, Tai Ho Chung, Cheorl-Ho Kim.   

Abstract

BACKGROUND: Matrix metalloproteases (MMP) and alpha-fetoproteins (AFP) are involved in hepatitis B virus (HBV)-induced chronic hepatitis. In the present study, we have determined the correlation between the MMP-9/MMP-9 ratio and AFP levels in the serum of patients during chronic viral B hepatitis.
METHODS: Twenty-eight healthy individuals (18 men and 10 women) with a mean age of 36.3 years (range 23-58 years) and 50 patients (42 men, 8 women) with a mean age of 39.7 years (range 22-61 years) participated in the study. Forty-eight participants had HBV and the remaining two were either hepatitis G virus (HGV) or hepatitis C virus (HCV) carriers. Values of patients were compared with those obtained from 12 blood donor controls (5 men, 7 women), mean age 36 years (range 21-46 years). Patients' sera were subjected to examination of hepatitis B surface (HBs) and hepatitis B early (Hbe) antigen, SGOT, SGPT, AFP, MMP-2 and MMP-9. Serum levels of MMP-2 and MMP-9 activities were measured by a zymogram protease assay and densitometric measurement. The ratios of MMP-9 to MMP-2 were calculated by dividing the densitometric results.
RESULTS: Compared with the healthy controls, the mean serum concentrations of MMP-2 were slightly increased in the chronic HBV patients. In contrast, compared with the healthy controls, the mean serum concentrations of MMP-9 were significantly increased in the chronic HBV patients. When the ratios of the MMP-9/MMP-2 and amounts of the serum AFP were compared, a specific correlation between these two parameters was observed. Higher amounts of AFP were detected in the patients with a low ratio of MMP-9/MMP-2. Patients with hepatocellular carcinoma (HCC) and cirrhosis showed relatively low MMP-9/MMP-2 ratios in chronic hepatitis B. In addition, AFP levels of HCC and cirrhosis were higher than in chronic HBV patients.
CONCLUSIONS: These results indicate that the AFP level and ratio of MMP-9 and MMP-2 is highly correlated in chronic HBV-induced hepatitis. Because the serum MMP activities were significantly varied between each stage of AFP production in liver disease, an individual profile of these parameters might serve as an easy accessing serum marker to monitor the progression of liver disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15086601     DOI: 10.1111/j.1440-1746.2004.03344.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  5 in total

1.  Matrix Metalloproteinase 9 Facilitates Hepatitis B Virus Replication through Binding with Type I Interferon (IFN) Receptor 1 To Repress IFN/JAK/STAT Signaling.

Authors:  Junbo Chen; Wei Xu; Yanni Chen; Xueping Xie; Yecheng Zhang; Chunqiang Ma; Qingyu Yang; Yang Han; Chengliang Zhu; Ying Xiong; Kailang Wu; Fang Liu; Yingle Liu; Jianguo Wu
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

2.  Matrix metalloproteinase-2 and -9 activities in the human lens epithelial cells and serum of steroid induced posterior subcapsular cataracts.

Authors:  Bhagwat V Alapure; Mamidipudi R Praveen; Devarshi U Gajjar; Abhay R Vasavada; Trilok J Parmar; Anshul I Arora
Journal:  Mol Vis       Date:  2012-01-11       Impact factor: 2.367

3.  Hemodialysis removes uremic toxins that alter the biological actions of endothelial cells.

Authors:  Kalliopi Zafeiropoulou; Theodora Bita; Apostolos Polykratis; Stella Karabina; John Vlachojannis; Panagiotis Katsoris
Journal:  PLoS One       Date:  2012-02-22       Impact factor: 3.240

4.  Novel Role for Matrix Metalloproteinase 9 in Modulation of Cholesterol Metabolism.

Authors:  Samuel Hernandez-Anzaldo; Vesna Brglez; Bianca Hemmeryckx; Dickson Leung; Janos G Filep; Jean E Vance; Dennis E Vance; Zamaneh Kassiri; Roger H Lijnen; Gérard Lambeau; Carlos Fernandez-Patron
Journal:  J Am Heart Assoc       Date:  2016-09-30       Impact factor: 5.501

5.  Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy.

Authors:  Massimiliano Castellazzi; Tiziana Bellini; Alessandro Trentini; Serena Delbue; Francesca Elia; Matteo Gastaldi; Diego Franciotta; Roberto Bergamaschi; Maria Cristina Manfrinato; Carlo Alberto Volta; Enrico Granieri; Enrico Fainardi
Journal:  Dis Markers       Date:  2016-06-02       Impact factor: 3.434

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.